Baird maintains an 'Outperform' on Vertex (VRTX); Building a Franchise Around Incivek; Pipeline Looks Like A Call Option

Baird maintains an 'Outperform' on Vertex (NASDAQ: VRTX) price target of $62.00.

Baird analyst says, "Recommend staying overweight VRTX through this period of pressure and volatility. The stock is trading on weekly script trends, and the bull case requires that Incivek launch remain a growth story to thread the needle until Cystic Fibrosis returns to center stage H1-12. While it may take more time to show up, this survey suggests docs beyond the top deciles/fastest movers may indeed help drive an incremental leg of growth, and it goes into our mosaic as a positive datapoint."

For more ratings news on Vertex click here and for the rating history of Vertex click here.

Shares of Vertex closed at $42.28 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• RBC Capital on Vertex (VRTX): 'SION Overhang Cleared; We Would Remain Buyers'
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform